Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Magnesium + eicosapentaenoic acid** is a combination product of two biologically active substances: **magnesium**, an essential mineral involved in neuromuscular function, cardiovascular health, and metabolic processes, and **eicosapentaenoic acid (EPA)**, an omega-3 polyunsaturated fatty acid derived from marine sources. EPA acts primarily as a precursor for less inflammatory eicosanoids and can reduce triglycerides and cardiovascular risk when taken in prescription form (such as icosapent ethyl)[1][2][6]. Magnesium supplementation supports electrolyte balance, cardiac rhythm, muscle contraction, and various enzymatic reactions. This combination is generally found in dietary supplement form, not as an approved pharmaceutical drug. Mechanistically, EPA modulates inflammation, reduces blood vessel constriction, and lowers clotting potential via alteration of eicosanoid signaling[6]. Magnesium supports cardiac electrical stability and metabolic functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium + eicosapentaenoic acid.